耐甲氧西林金黄色葡萄球菌的体外头孢唑林持续敏感。
Continued in vitro cefazolin susceptibility in methicillin-susceptible Staphylococcus aureus.
机构信息
Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
Seattle Children's Microbiology Laboratory, Seattle, USA.
出版信息
Ann Clin Microbiol Antimicrob. 2018 Feb 20;17(1):5. doi: 10.1186/s12941-018-0257-x.
OBJECTIVES
In vitro trends of cefazolin and ceftriaxone susceptibilities from pediatric clinical isolates of methicillin-susceptible Staphylococcus aureus (MSSA) between 2011 and 2016 were analyzed for surveillance.
METHODS
Our laboratory continues to use agar disk diffusion for staphylococcal susceptibilities applying Clinical Laboratory Standard Institute's 2012 breakpoints.
RESULTS
A total of 3992 MSSA clinical isolates in the last 6 years were analyzed for their in vitro cefazolin and ceftriaxone susceptibilities. While all MSSA isolates exhibited cefazolin susceptibilities within the "susceptible" zone range, there have been a proportion of isolates with ceftriaxone susceptibilities falling in "intermediate" zones, ranging from 2.6% in 2011 to 8.3% in 2016.
CONCLUSIONS
Cefazolin continues to be the recommended agent for MSSA treatment at our institution, reflected by the finding that only 2% (6/321) of patients who received ceftriaxone as definitive therapy for MSSA bacteremia during the study period. We have confirmed the cefoxitin-predicted MSSA susceptibility to cefazolin, but have found concerning drifts in ceftriaxone susceptibilities by continued in vitro monitoring over the last 6 years.
目的
分析 2011 年至 2016 年间耐甲氧西林金黄色葡萄球菌（MSSA）儿童临床分离株中头孢唑林和头孢曲松敏感性的体外趋势，以进行监测。
方法
我们的实验室继续使用琼脂扩散法进行葡萄球菌药敏试验，采用临床实验室标准化研究所 2012 年的折点。
结果
在过去 6 年中，共分析了 3992 株 MSSA 临床分离株，以评估其体外头孢唑林和头孢曲松敏感性。虽然所有 MSSA 分离株均表现出头孢唑林敏感性在“敏感”范围内，但有一定比例的分离株头孢曲松敏感性落在“中介”范围内，范围从 2011 年的 2.6%到 2016 年的 8.3%。
结论
头孢唑林仍然是我们机构治疗 MSSA 的推荐药物，这反映在研究期间只有 2%（6/321）接受头孢曲松作为 MSSA 菌血症确定性治疗的患者。我们已经证实了头孢西丁预测的 MSSA 对头孢唑林的敏感性，但通过过去 6 年的持续体外监测，发现头孢曲松敏感性存在漂移。
Zotero 插件